US44148G2049 - Common Stock
HOTH THERAPEUTICS INC
NASDAQ:HOTH (4/25/2024, 7:00:01 PM)
1.17
0 (0%)
Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. The company is headquartered in New York City, New York and currently employs 2 full-time employees. The company went IPO on 2019-02-15. The firm is also focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer; a treatment for mast-cell derived cancers and anaphylaxis; a treatment for traumatic brain injury and ischemic stroke, and a treatment and/or prevention for Alzheimer’s or other neuroinflammatory diseases. The company also has assets being developed for atopic dermatitis; a treatment for asthma and allergies using inhalational administration, and a treatment for acne as well as inflammatory bowel diseases. The company is also developing a diagnostic device via a mobile device. Its development products include HT-001, HT-KIT, HT-TBI and HT-ALZ. Its preclinical development products include HT-003, HT-004, and HT-002. The company also has interests in certain other assets being developed by third parties, including a treatment for patients with lupus.
HOTH THERAPEUTICS INC
1 Rockefeller Plz Ste 1039
New York City NEW YORK 10020
P: 15515782261
CEO: Robb Knie
Employees: 2
Website: https://hoththerapeutics.com/
/PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, today announced the entry into a definitive agreement for...
/PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, is excited to announce a significant breakthrough by its...
/PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), is pleased to unveil positive pre-clinical research showcasing the potential of HT-ALZ, an innovative...
/PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused biopharmaceutical company, today announced that it will continue its work with...
/PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that it has completed bioanalytical method...
/PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Robb Knie, Chief Executive Officer, is scheduled to...
Here you can normally see the latest stock twits on HOTH, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: